Stelmakh Edward, Chief Finance and Strategy Officer at OptimizeRx Corp ($OPRX), made one open market sale of common shares in the last year, totaling $18,752. His most recent OPRX insider sale occurred on December 19, 2025. Among 11,678 insiders with open market sales, his activity ranks 11,069th by volume, well below the average of $8.6 million across roughly 6 transactions per insider. He reported no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 23, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | Chief Finance & Strat Officer | F | Common Stock | 3658 | $12.74 | 123,172.0000 | 20,333,839 | 2.88% | 0.02% |
| Dec. 19, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | Chief Finance & Strat Officer | M | Restricted Stock Units | 5237 | $0.00 | 5,237.0000 | 20,333,839 | 50.00% | 0.03% |
| Dec. 19, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | Chief Finance & Strat Officer | M | Common Stock | 5237 | $0.00 | 128,218.0000 | 20,333,839 | 4.26% | 0.03% |
| Dec. 19, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | Chief Finance & Strat Officer | F | Common Stock | 1388 | $13.51 | 126,830.0000 | 20,333,839 | 1.08% | 0.01% |
| Dec. 19, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | Chief Finance & Strat Officer | M | Common Stock | 5237 | $0.00 | 128,218.0000 | 20,333,839 | 4.26% | 0.03% |
| Dec. 19, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | Chief Finance & Strat Officer | M | Restricted Stock Units | 5237 | $0.00 | 5,237.0000 | 20,333,839 | 50.00% | 0.03% |
| Dec. 19, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | Chief Finance & Strat Officer | S | Common Stock | 1388 | $13.51 | 126,830.0000 | 20,333,839 | 1.08% | 0.01% |
| Oct. 3, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | Chief Finance & Strat Officer | M | Common Stock | 16623 | $0.00 | 127,387.0000 | 20,333,839 | 15.01% | 0.08% |
| Oct. 3, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | Chief Finance & Strat Officer | F | Common Stock | 4406 | $18.75 | 122,981.0000 | 20,333,839 | 3.46% | 0.02% |
| Oct. 3, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | Chief Finance & Strat Officer | M | Restricted Stock Units | 16623 | $0.00 | 0.0000 | 20,333,839 | 100.00% | 0.08% |
| Aug. 21, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | A | Common Stock | 15625 | $0.00 | 110,764.0000 | 20,297,388 | 16.42% | 0.08% |
| Aug. 21, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | A | Stock Option | 35156 | $0.00 | 35,156.0000 | 20,297,388 | 9999.99% | 0.17% |
| Feb. 15, 2025 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | F | Common Stock | 2156 | $6.64 | 95,139.0000 | 20,194,697 | 2.22% | 0.01% |
| Feb. 15, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | A | Common Stock | 0 | $0.00 | 33,365.0000 | 19,899,679 | 0.00% | 0.00% |
| Dec. 23, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | A | Stock Option | 77742 | $0.00 | 77,742.0000 | 20,069,432 | 9999.99% | 0.39% |
| Dec. 23, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | A | Common Stock | 41408 | $0.00 | 97,295.0000 | 20,069,432 | 74.09% | 0.21% |
| Dec. 19, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Restricted Stock Units | 5237 | $0.00 | 10,474.0000 | 20,069,432 | 33.33% | 0.03% |
| Dec. 19, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Common Stock | 5237 | $0.00 | 38,603.0000 | 20,069,432 | 15.70% | 0.03% |
| Dec. 19, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | F | Common Stock | 1316 | $4.75 | 37,287.0000 | 20,069,432 | 3.41% | 0.01% |
| Oct. 11, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Restricted Stock Units | 8222 | $0.00 | 0.0000 | 20,069,432 | 100.00% | 0.04% |
| Oct. 11, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Common Stock | 8222 | $0.00 | 35,432.0000 | 20,069,432 | 30.22% | 0.04% |
| Oct. 11, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | F | Common Stock | 2066 | $6.63 | 33,366.0000 | 20,069,432 | 5.83% | 0.01% |
| Oct. 3, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Restricted Stock Units | 16622 | $0.00 | 16,583.0000 | 20,069,432 | 50.06% | 0.08% |
| Oct. 3, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Common Stock | 16622 | $0.00 | 31,387.0000 | 20,069,432 | 112.58% | 0.08% |
| Oct. 3, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | F | Common Stock | 4177 | $7.83 | 27,210.0000 | 20,069,432 | 13.31% | 0.02% |
| Feb. 15, 2024 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | A | Common Stock | 7083 | $0.00 | 14,765.0000 | 19,899,679 | 92.20% | 0.04% |
| Oct. 11, 2023 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Common | 8221 | $0.00 | 28,034.0000 | 0 | 41.49% | 0.00% |
| Oct. 11, 2022 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | F | Common Stock | 3539 | $15.17 | 7,682.0000 | 0 | 31.54% | 0.00% |
| Dec. 19, 0023 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | A | Restricted Stock Units | 15711 | $0.00 | 15,711.0000 | 0 | 9999.99% | 0.00% |
| Dec. 19, 0023 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | A | Stock Option | 15711 | $0.00 | 15,711.0000 | 0 | 9999.99% | 0.00% |
| Oct. 11, 2023 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | F | Common Stock | 2066 | $7.15 | 29,537.0000 | 0 | 6.54% | 0.00% |
| Oct. 11, 2022 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Restricted Stock Units | 8221 | $0.00 | 16,443.0000 | 0 | 33.33% | 0.00% |
| Oct. 11, 2023 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Restricted Stock Units | 8221 | $0.00 | 8,222.0000 | 0 | 50.00% | 0.00% |
| Oct. 11, 2022 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Common Stock | 8221 | $0.00 | 25,448.0000 | 0 | 47.72% | 0.00% |
| Oct. 11, 2023 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Common Stock | 6155 | $0.00 | 31,603.0000 | 0 | 24.19% | 0.00% |
| Oct. 3, 2023 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Common Stock | 16662 | $0.00 | 21,344.0000 | 0 | 355.87% | 0.00% |
| Oct. 3, 2023 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | F | Common Stock | 4117 | $7.06 | 17,227.0000 | 0 | 19.29% | 0.00% |
| Oct. 3, 2023 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Restricted Stock Units | 16662 | $0.00 | 33,205.0000 | 0 | 33.41% | 0.00% |
| Oct. 11, 2022 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Common Stock | 8221 | $0.00 | 11,221.0000 | 0 | 274.03% | 0.00% |
| Oct. 11, 2022 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | M | Restricted Stock Units | 8221 | $0.00 | 16,443.0000 | 0 | 33.33% | 0.00% |
| Oct. 11, 2022 | OptimizeRx Corp | $OPRX | Stelmakh Edward | CFO/COO | F | Common Stock | 6539 | $15.17 | 4,682.0000 | 0 | 58.27% | 0.00% |